Comparable Analysis of Outcomes for Allogeneic Peripheral Blood Stem Cell Transplantation from Matched Related and Matched Unrelated Donors in Acute Myeloid LeukemiaLee S.J.a · Kang B.W.a · Moon J.H.a · Chae Y.S.a · Kim J.G.a · Jung J.S.b · Cho G.-J.b · Jo D.-Y.c · Kim Y.K.h · Kim H.J.h · Ryoo H.-M.d · Eom H.S.i · Le S.M.e · Joo Y.-D.e · Won J.-H.j · Park M.R.f · Kim M.K.g · Hyun M.S.g · Sohn S.K.a
Departments of Hematology and Oncology,aKyungpook National University Hospital, Daegu, bPusan National University Hospital, Pusan, cChungnam National University Hospital, Daejeon, dDaegu Catholic University Hospital, Daegu, eInje University Hospital, Pusan, fWonKwang University Hospital, Iksan, and gYeungnam University Medical Center, Daegu, and Departments of Hematology, hChonnam National University Hwasun Hospital, Hwasun, iNational Cancer Center of Korea, and jSoonchunhyang University Hospital, Bucheon, South Korea
This study compared the results of allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated and related donors in 142 consecutive patients with acute myeloid leukemia (AML). The cumulative incidence of acute graft-versus-host disease (GVHD) was 37.6% in the related PBSCT group and 53.7% in the unrelated PBSCT group. The cumulative incidence of extensive chronic GVHD was also higher in the unrelated PBSCT group (19.5%) than in the related PBSCT group (8.9%). The overall survival rate at 4 years was 62.4 ± 5.4 and 53.8 ± 1.2% (p = 0.535) in the related and unrelated PBSCT group, respectively. In a multivariate analysis, unrelated PBSCT was identified as a risk factor for the development of extensive chronic GVHD (hazard ratio = 3.019, p = 0.027). Unfavorable cytogenetics and the disease status at the time of transplantation were found to be related to overall survival. In the case of high-risk AML, the survival rate and relapse incidence were significantly better in the matched unrelated PBSCT group (p = 0.047 and 0.039, respectively). In conclusion, the allogeneic PBSCT outcomes for AML were comparable in the matched related and matched unrelated groups. Nonetheless, for high-risk AML patients, matched unrelated PBSCT was found to be preferable to matched related PBSCT.
© 2011 S. Karger AG, Basel